natgillin/translations-raw huggingface dataset:
In 2 randomised, double-blind studies encompassing a total of 1,094 adult patients receiving chemotherapy that included cisplatin  70 mg/m2, aprepitant in combination with an ondansetron/dexamethasone regimen (see section 4.2) was compared with a standard regimen (placebo plus ondansetron 32 mg intravenously administered on Day 1 plus dexamethasone 20 mg orally on Day 1 and 8 mg orally twice daily on Days 2 to 4).
U dva randomizirana, dvostruko slijepa ispitivanja s ukupno 1094 odraslih bolesnika koji primaju kemoterapiju koja je uključivala cisplatin u dozi od ≥70 mg/m2, uspoređen je režim liječenja aprepitantom u kombinaciji s ondanzetronom/deksametazonom (vidjeti dio 4.2) sa standardnim režimom (placebo s ondanzetronom primijenjenim intravenski u dozi od 32 mg 1. dana te peroralnim deksametazonom u dozi od 20 mg 1. dan i 8 mg dvaput na dan 2. do 4. dana).
In 2 studies in healthy subjects the median times to the peak plasma concentrations were 1 and 3 hours after dosing.
U dva ispitivanja u zdravih ispitanika, medijan vremena do postizanja vršnih koncentracija u plazmi iznosio je 1 i 3 sata nakon doziranja.
In 2 studies with extended interval dosing of erythropoietin (3 times per week, once weekly, once every 2 weeks and once every 4 weeks) some patients with longer dosing intervals did not maintain adequate haemoglobin levels and reached protocol-defined haemoglobin withdrawal criteria (0% in once weekly, 3.7% in once-every-2-weeks and 3.3% in the once-every-4-weeks groups).
U 2 ispitivanja s produljenim intervalom doziranja eritropoetina (3 puta tjedno, jedanput tjedno, jednom svaka 2 tjedna i jednom svaka 4 tjedna) u nekih bolesnika s dužim intervalom doziranja prikladna razina hemoglobina nije održana i dostignut je protokolom definiran kriterij hemoglobina za povlačenje (0% kod doziranja jednom tjedno; 3,7% kod doziranja jednom svaka 2 tjedna i 3,3% kod doziranja jednom svaka 4 tjedna).
In 2% and 0.3% of the simeprevir-treated patients grade 3 or 4 ‘blood bilirubin increased’ was reported, respectively (pooled phase 3 studies).
U 2% odnosno 0,3% bolesnika liječenih simeprevirom bio je prijavljen ‘povišen bilirubin u krvi’ stupnja 3 ili 4 (objedinjena ispitivanja faze 3).
In 2-year carcinogenicity studies, no carcinogenicity was observed, but there was an increased incidence of hepatocellular adenomas in mice, which was not statistically significant, at systemic exposures 5.7-fold higher than those in humans at the recommended therapeutic dose.
U dvogodišnjim istraživanjima karcinogenosti nije opažena karcinogenost, ali je zabilježena povećana incidencija hepatocelularnih adenoma u miševa, koja nije bila statistički značajna, pri sistemskoj izloženosti 5,7 puta većoj od izloženosti u ljudi pri preporučenim terapijskim dozama.
In 2-year controlled clinical trials in MS patients TYSABRI treatment was associated with increases in circulating lymphocytes, monocytes, eosinophils, basophils and nucleated red blood cells.
U 2-godišnjem kontroliranom kliničkom ispitivanju u bolesnika s multiplom sklerozom liječenje TYSABRIJEM bilo je povezano s povećanjem broja limfocita, monocita, eozinofila, bazofila i crvenih krvnih stanica s jezgrom.
In 2-year subcutaneous carcinogenicity studies, non-lethal C-cell thyroid tumors were seen in rats and mice and are considered to be caused by a non-genotoxic GLP-1 receptor-mediated mechanism to which rodents are particularly sensitive.
U 2-godišnjim istraživanjima karcinogenosti nakon supkutane primjene u štakora i miševa primijećeni su nesmrtonosni tumori C-stanica štitnjače za koje se smatra da su uzrokovani negenotoksičnim mehanizmom posredovanim receptorom GLP-1, na koji su glodavci iznimno osjetljivi.
In 20 placebo-controlled studies, conducted in a variety of therapeutic indications, a total of 2,486 patients were treated with bosentan at daily doses ranging from 100 mg to 2000 mg and 1,838 patients were treated with placebo.
U 20 placebom kontroliranih studija, provedenih kod različitih terapijskih indikacija, ukupno 2486 bolesnika dobivalo je bosentan u dnevnim dozama od 100 mg do 2000 mg, a 1838 bolesnika dobivalo je placebo.
In 22 CP patients evaluated for efficacy Tasigna induced a 32% MCyR rate and a 50% CHR rate.
U 22 bolesnika u kroničnoj fazi u kojih je procijenjena djelotvornost, Tasigna je rezultirala stopom MCyR-a od 32%, te stopom CHR-a od 50%.
In 23 healthy subjects the concentration of desipramine, a CYP2D6 substrate, was unaffected when 25 mg of temsirolimus was co-administered.
Kod 23 zdrava ispitanika koncentracija desipramina, koji je supstrat CYP2D6, bila je nepromijenjena kada je istovremeno primijenjeno 25 mg temsirolimusa.
In 24 healthy volunteers receiving Rapamune tablets with a high-fat meal, Cmax, tmax and AUC showed increases of 65%, 32%, and 23%, respectively.
U 24 zdrava dobrovoljca koji su primali tablete Rapamunea s obrokom bogatom mastima došlo je do porasta Cmax za 65%, tmax za 32% i AUC za 23%.
In 27 reports of Fluenz administration to pregnant women from the US Vaccine Adverse Event Reporting System, no unusual patterns of pregnancy complications or foetal outcomes were observed.
U 27 izvještaja američkog sustava za prijavu štetnih posljedica cjepiva (VAERS) o primjeni cjepiva Fluenz na trudnicama, nisu zabilježeni neuobičajeni oblici komplikacija u trudnoći ili fetalnih ishoda.
In 27 reports of T/LAIV administration to pregnant women from the US Vaccine Adverse Event Reporting System (VAERS), no unusual patterns of pregnancy complications or foetal outcomes were observed.
U 27 izvještaja američkog sustava za prijavu štetnih posljedica cjepiva (VAERS) o primjeni T/LAIV cjepiva u trudnica, nisu zabilježeni neuobičajeni oblici komplikacija u trudnoći ili fetalnih ishoda.
In 3 additional cases where severe hyponatremia was associated with neurological symptoms such as brain oedema or major confusion and cerebral oedema, causality could also not be excluded.
U 3 dodatna slučaja gdje je teška hiponatrijemija bila povezana s neurološkim simptomima, kao što su edem mozga ili jaka konfuzija i cerebralni edem, uzročno-posljedična veza također se nije mogla isključiti.
In 3 controlled and 2 uncontrolled clinical studies, among adult chronic ITP patients receiving eltrombopag (n=446), 17 subjects experienced a total of 19 TEEs, which included (in descending order of occurrence) deep vein thrombosis (n=6), pulmonary embolism (n=6), acute myocardial infarction (n=2), cerebral infarction (n=2), embolism (n=1) (see section 4.4).
U 3 kontrolirana i 2 nekontrolirana klinička ispitivanja, među odraslim bolesnicima s kroničnom ITP koji su primali eltrombopag (n=446), 17 ispitanika je doživjelo ukupno 19 TED, koji su uključivali (navedeni prema padajućem redoslijedu pojavljivanja): duboku vensku trombozu (n=6), plućnu emboliju (n=6), akutni infarkt miokarda (n=2), cerebralni infarkt (n=2), emboliju (n=1) (vidjeti dio 4.4).
In 3 patients, the daily cysteamine dose exceeded the recommended maximum of 1.95 g/m(2)/day.
U 3 bolesnika dnevna doza cisteamina prelazila je preporučenu maksimalnu dozu od 1,95 g/m(2)/dan.
In 3.8% of the patients symptoms of SIRS were observed within 24 hours after catumaxomab infusion.
U 3,8% bolesnika simptomi sindroma sistemskog upalnog odgovora uočeni su unutar 24 sata nakon infuzije katumaksomaba.
In 30-week placebo-controlled clinical trials with immediate-release exenatide, concomitant use of exenatide and HMG CoA reductase inhibitors was not associated with consistent changes in lipid profiles (see section 5.1).
U 30-tjednim placebom kontroliranim kliničkim ispitivanjima eksenatida s trenutnim oslobađanjem, istodobna primjena eksenatida i inhibitora HMG KoA reduktaze nije bila povezana s konzistentnim promjenama lipidnih profila (vidjeti dio 5.1).
In 34 % of courses with severe neutropenia, the duration was > 7 days.
U 34% ciklusa s teškom neutropenijom trajanje je bilo >7 dana.
In 34% of patients receiving 0.6 mg Signifor and 41% of patients receiving 0.9 mg Signifor, urine cortisol levels decreased by at least 50% within six months.
U 34% bolesnika koji su primali lijek Signifor u dozi od 0,6 mg i 41% bolesnika koji su primali lijek Signifor u dozi od 0,9 mg, zabilježeno je smanjenje koncentracije kortizola u urinu za najmanje 50% u roku od šest mjeseci.
In 36 healthy male and female subjects given a single oral dose of palonosetron capsules
U 36 zdravih muškaraca i žena koji su primili jednu oralnu dozu palonosetrona u kapsuli od
In 4 controlled and 2 uncontrolled clinical studies, 530 chronic adult ITP patients were treated with eltrombopag.
U 4 kontrolirana i 2 nekontrolirana klinička ispitivanja, 530 odraslih bolesnika s kroničnim ITP-om bilo je liječeno eltrombopagom.
In 4 rectal diazepam controlled studies and one study versus intravenous diazepam, in a total of 688 children, cessation of visible signs of seizures within 10 minutes was observed in 65% to 78% of children receiving oromucosal midazolam.
U 4 ispitivanja midazolama kontrolirana rektalnom primjenom diazepama te u jednom ispitivanju usporedbe midazolama i intravenskog diazepama provedenim na ukupno 688 djece, u 65% do 78% djece koja su primala midazolam za usnu sluznicu opažen je prestanak vidljivih znakova napadaja unutar 10 minuta.
In 43 CAPS patients followed for up to 5 years neutropenia was reported in 2 patients.
U 43 bolesnika s CAPS-om koji su praćeni najdulje do 5 godina neutropenija je prijavljenja u 2 bolesnika.
In 44 patients with schizophrenia >65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
44 bolesnika sa shizofrenijom u dobi iznad 65 godina doziranje od 5 do 20 mg/dan nije bilo povezano ni sa kakvim razlikovnim profilom nuspojava.
In 44 patients with schizophrenia  65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
44 bolesnika sa shizofrenijom u dobi iznad 65 godina doziranje od 5 do 20 mg/dan nije bilo povezano ni sa kakvim posebnim profilom nuspojava.
In 44 patients with schizophrenia  65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
U 44 bolesnika sa shizofrenijom, u dobi od 65 godina, doziranje od 5 do 20 mg/dan nije bilo povezano ni sa kakvim razlikovnim profilom štetnih događaja.
In 46 % of courses with moderate to severe anaemia, the duration was > 7 days.
U 46% ciklusa s umjerenom do teškom anemijom, trajanje je bilo > 7 dana.
In 5 cases pallor was associated with systemic events such as hypotension which is already an identified adverse drug reaction of Mirvaso.
U 5 slučajeva bljedilo je bilo povezano sa sistemskim događajima kao što su hipotenzija koja je već identificirana kao nuspojava lijeka Mirvaso.
In 5 small, open label, uncontrolled studies (number of patients ranged from 9-22, total N = 72), Epoetin alfa has been administered subcutaneously in children at starting doses of 100 IU/kg/week to 150 IU/kg/week with the possibility to increase up to 300 IU/kg/week.
U 5 malih, otvorenih, nekontroliranih ispitivanja (broj bolesnika u rasponu od 9-22, ukupan N = 72), epoetin alfa se u djece primjenjivao supkutano u početnim dozama od 100 IU/kg/tjedno do 150 IU/kg/tjedno uz mogućnost povećanja do 300 IU/kg/tjedno.
In 5 years post vaccination, the percentage of Menveo recipients with hSBA ≥ 1:8 remained significantly higher compared with ACWY-PS recipients for serogroups C and Y. Higher hSBA GMTs were observed for serogroups W135 and Y (Table 7).
Pet godina nakon cijepljenja, postotak primatelja cjepiva Menveo s hSBA ≥ 1:8 ostao je znatno veći u usporedbi s primateljima cjepiva ACWY-PS za serogrupe C i Y. Viši hSBA GMTs primijećen je za serogrupe W135 i Y (Tablica 7).
In 5,673 vaccinated infants (2,834 in the vaccine group) protective efficacy was measured as a reduction in the incidence of rotavirus (RV) gastroenteritis caused by vaccine G genotypes (G1- G4) that occurred at least 14 days after the third dose of vaccine through the first full rotavirus season after vaccination.
U 5673 cijepljene dojenčadi (2834 u skupini koja je primila cjepivo) zaštitna djelotvornost cjepiva mjerena je smanjenjem incidencije gastroenteritisa uzrokovanog G genotipovima (G1-G4) rotavirusa obuhvaćenih cjepivom u vremenu od najmanje 14 dana nakon primitka treće doze cjepiva pa sve do kraja cijele prve sezone pojave rotavirusa nakon cijepljenja.
In 5.1% of patients pyrexia reached an intensity of CTCAE grade 3 as it was the case with cytokine release syndrome (1.0%), chills (0.8%), nausea (3.4%), vomiting (4.4%), dyspnoea (1.6%) and hypo-
U 5,1% bolesnika pireksija je dosegla je intenzitet CTCAE stupnja 3 kao i sindrom otpuštanja citokina (1,0%), zimica (0,8%), mučnina (3,4%), povraćanje (4,4%), dispneja (1,6%) i hipo
In 6 additional patients reticulin was observed upon bone marrow biopsy (see section 4.4).
U 6 dodatnih bolesnika odlaganje retikulina nađeno je analizom biopsije koštane srži (vidjeti dio 4.4).
In 6 additional studies (two comparative vs. caspofungin and four non- comparative), 636 patients including 53 neutropenic patients and 131 patients with deep tissue infection were studied; the mean durations of intravenous treatment in neutropenics patients and patients with deep tissue infection in these studies were 10.0 (range, 1 to 42 days) and 14.0 (range, 1 to 42 days) days, respectively.
U 6 dodatnih ispitivanja (dva usporedna naspram kaspofungina i četiri neusporedna) proučavana su 636 bolesnika uključujući 53 bolesnika s neutropenijom te 131 bolesnika s dubokom infekcijom tkiva; intravensko liječenje trajalo je prosječno 10,0 (raspon od 1 do 42 dana) dana za bolesnike s neutropenijom, odnosno 14,0 (raspon od 1 do 42 dana) dana za bolesnike s infekcijom dubokog tkiva.
In 6 initial main studies involving around 2,300 patients infected with hepatitis C virus genotypes 1a or 1b, Exviera in combination with Viekirax was effective in clearing the virus from the blood.
U šest inicijalnih ispitivanja koja su uključivala oko 2300bolesnika zaraženih genotipom 1a ili 1b virusa hepatitisa C, lijek Exviera je u kombinaciji s Viekiraxom bio djelotvoran u čišćenju virusa iz krvi.
In 6 initial main studies involving around 2,300 patients infected with hepatitis C virus genotypes 1a or 1b, Viekirax in combination with dasabuvir was effective in clearing the virus from the blood.
U šest inicijalnih ispitivanja koja su uključivala oko 2300 osoba, bolesnici zaraženi genotipom 1a ili 1b virusa hepatitisa C, lijek Viekirax je u kombinaciji s dasabuvirom bio djelotvoran u čišćenju virusa iz krvi.
In 6-month carcinogenicity studies in transgenic mice, there was an increased incidence of benign, ovarian granulosa-cell tumours in female mice given 150 or 500 mg/kg/day.
U 6-mjesečnim ispitivanjima kancerogenosti na transgeničnim miševima zabilježena je povećana incidencija benignih tumora granuloznih stanica jajnika u ženki miševa kojima je primijenjena doza od 150 ili 500 mg/kg na dan.
In 6-month carcinogenicity studies in transgenic mice, there was an increased incidence of benign, ovarian granulosa-cell tumours in female mice given 150 or 500 mg/kg/day.
U 6-mjesečnim ispitivanjima kancerogenosti provedenima na transgeničnim miševima zabilježena je povećana incidencija benignih tumora granuloznih stanica jajnika u ženki miševa kojima je primijenjena doza od 150 ili 500 mg/kg na dan.
In 6-month controlled clinical studies, the rate of serious infections with tocilizumab 8 mg/kg plus DMARDs was 5.3 events per 100 patient years exposure compared to 3.9 events per 100 patient years exposure in the placebo plus DMARD group.
U 6-mjesečnim kontroliranim kliničkim ispitivanjima, stopa ozbiljnih infekcija uz tocilizumab u dozi od 8 mg/kg s DMARD-om iznosila je 5,3 infekcije na 100 bolesnik-godina izloženosti u usporedbi s 3,9 infekcija na 100 bolesnik-godina izloženosti u skupini koja je primala placebo i DMARD.
In 61 of these 117patients FIP1L1- PDGFRα fusion kinase was identified.
U 61 od tih 117 bolesnika identificirana je FIP1L1-PDGFRα fuzijska kinaza.
In 7 paediatric patients under 2 years of age who received RAVICTI for up to 12 months, the concentrations of PAA, PBA, and PAGN did not increase over the treatment period and the overall median PAA, PBA, and PAGN concentrations in these patients were similar to those observed in older paediatric age groups.
Kod 7 pedijatrijskih bolesnika mlađih od 2 godine koji su primali lijek RAVICTI do 12 mjeseci, koncentracije PAA, PBA i PAGN nisu se povećavale u razdoblju liječenja a ukupni medijani koncentracija PAA, PBA i PAGN kod tih bolesnika bili su slični onima zabilježenima kod starijih pedijatrijskih dobnih skupina.
In 8 cases, there was evidence of positive dechallenge following discontinuation of UMEC/VI.
U 8 slučajeva postojali su dokazi povlačenja nuspojave nakon prekida primjene umeklidinijeva bromida/vilanterola (engl. positive dechallenge).
In 8 subjects with severe renal impairment to whom a single dose of 30 mg apremilast was administered, the AUC and Cmax of apremilast increased by approximately 89% and 42%, respectively.
U 8 ispitanika s teškim oštećenjem funkcije bubrega kojima je primijenjena jedna doza od 30 mg apremilasta, vrijednost AUC-a apremilasta povećala se za približno 89%, a Cmax za 42%.
In 80-85% of all patients treated with either dose, Repatha demonstrated a ≥ 50% reduction in LDL-C at the mean of weeks 10 and 12.
U 80-85% svih bolesnika liječenih s bilo kojom od navedenih doza, Repatha je pokazala smanjenje LDL-C-a od ≥ 50% pri srednjoj vrijednosti u10. i 12. tjednu.
In 9-15 year-old boys and girls (Protocol 002), persistence of antibody response has been demonstrated for at least 3 years; depending on HPV type, 93 to 99% of subjects were seropositive.
U dječaka i djevojčica u dobi od 9 do 15 godina (Protokol 002), dokazano je da odgovor protutijela traje najmanje 3 godine; ovisno o tipu HPV-a, 93 do 99% ispitanika bilo je seropozitivno.
In 95 of these patients, the disease had not responded to both fludarabine and alemtuzumab, and in 112, treatment with fludarabine had failed but they had not been treated with alemtuzumab because this medicine was not suitable for them.
Kod 95 od tih bolesnika bolest nije reagirala ni na fludarabin ni na alemtuzumab, a kod njih 112 liječenje fludarabinom nije uspjelo, ali bolesnici nisu bili liječeni alemtuzumabom jer taj lijek za njih nije bio prikladan.
In a 1 year study, CE 0.45 mg/bazedoxifene 20 mg showed a significant difference from baseline in lumbar spine BMD (+1.52%) at Month 12 compared to placebo.
U jednogodišnjem ispitivanju liječenje s 0,45 mg KE/20 mg bazedoksifena pokazalo je znatnu razliku u odnosu na početne vrijednosti BMD-a lumbalne kralježnice (+1,52%) u 12. mjesecu u usporedbi s placebom.
In a 1-month, oral gavage dose-range finding study (0, 10, 25, 75, or 200 mg/kg/day) with continuous daily dosing in rasH2 transgenic mice, carcinoma and hyperplasia of Brunner’s glands of the duodenum were observed at the highest dose (200 mg/kg/day) tested.
U jednomjesečnom istraživanju radi utvrđivanja raspona doza (0, 10, 25, 75 ili 200 mg/kg na dan) u rasH2 transgeničnih miševa, s kontinuiranom dnevnom primjenom lijeka prisilnim hranjenjem, pri najvišoj ispitivanoj dozi (200 mg/kg na dan) opaženi su karcinom i hiperplazija Brunnerovih žlijezda dvanaesnika.
In a 104-week carcinogenicity study with prolonged-release exenatide a statistically significant increase in thyroid C-cell tumour incidence (adenomas and / or carcinomas) was observed in rats at all doses (1.4- to 26- fold the human clinical exposure with prolonged-release exenatide).
U ispitivanju karcinogenosti eksenatida s produljenim oslobađanjem, u trajanju od 104 tjedna, opaženo je statistički značajno povećanje incidencije tumora C-stanica štitnjače (adenomi i/ili karcinomi) u štakora pri svim dozama (1,4 do 26 puta veća izloženost od kliničke izloženosti kod primjene eksenatida s produljenim oslobađanjem u ljudi).
In a 104-week carcinogenicity study with prolonged-release exenatide a statistically significant increase in thyroid C-cell tumour incidence (adenomas and / or carcinomas) was observed in rats at all doses (1.4- to 26-fold the human clinical exposure with prolonged-release exenatide).
U ispitivanju karcinogenosti eksenatida s produljenim oslobađanjem, u trajanju od 104 tjedna, opaženo je statistički značajno povećanje incidencije tumora C-stanica štitnjače (adenomi i/ili karcinomi) u štakora pri svim dozama (1,4 do 26 puta veća izloženost od kliničke izloženosti kod primjene eksenatiduas produljenim oslobađanjem u ljudi).
In a 104­week clinical trial, 57% of patients with type 2 diabetes treated with insulin degludec in combination with metformin achieved a target HbA1c <7% and the remaining patients continued in a 26­week open label trial and were randomised to add liraglutide or a single dose of insulin aspart (with the largest meal).
U kliničkom ispitivanju koje je trajalo 104 tjedna, 57% bolesnika sa šećernom bolešću tipa 2 liječenih degludek inzulinom u kombinaciji s metforminom postiglo je ciljni HbA1c <7%, a preostali bolesnici nastavili su sudjelovati u 26-tjednom, otvorenom ispitivanju te su randomizirani tako da je liječenju dodan liraglutid ili jedna doza aspart inzulina (uz najveći obrok).
In a 12 month recurrence prevention study in manic episode patients who achieved remission on olanzapine and were then randomised to olanzapine or placebo, olanzapine demonstrated statistically significant superiority over placebo on the primary endpoint of bipolar recurrence.
U 12-mjesečnom ispitivanju prevencije relapsa u bolesnika s epizodom manije koji su postigli remisiju na olanzapinu, a zatim su randomizirani u skupinu koja je uzimala olanzapin ili placebo, olanzapin je pokazao statistički značajnu prednost nad placebom u primarnoj mjeri ishoda – relapsu bipolarnog poremećaja.
In a 12 week study involving peritoneal dialysis patients however, similar iPTH reductions were seen compared with patients receiving calcium acetate.
U 12-tjednom ispitivanju koje je uključivalo bolesnike na peritonealnoj dijalizi uočena su slična smanjenja vrijednosti iPTH-a kao u bolesnika koji su primali kalcijev acetat.
In a 12 week study involving peritoneal dialysis patients however, similar iPTH reductions were seen compared with patients receiving calcium acetate.
U 12-tjednom ispitivanju koje je uključivalo bolesnike na peritonealnoj dijalizi, uočena su slična smanjenja vrijednosti iPTH-a kao u bolesnika koji su primali kalcijev acetat.
In a 12 week study involving peritoneal dialysis patients however, similar iPTH reductions were seen compared with patients receiving calcium acetate.
U 12-tjednom ispitivanju koje je uključivalo bolesnike na peritonejskoj dijalizi uočena su slična smanjenja vrijednosti iPTH-a kao u bolesnika koji su primali kalcijev acetat.
In a 12 week study involving peritoneal dialysis patients however, similar iPTH reductions were seen compared with patients receiving calcium acetate.
U 12-tjednom ispitivanju koje je uključivalo bolesnike na peritonejskoj dijalizi, uočena su slična smanjenja vrijednosti iPTH-a kao u bolesnika koji su primali kalcijev acetat.
In a 12-month recurrence prevention study in manic episode patients who achieved remission on olanzapine and were then randomised to olanzapine or placebo, olanzapine demonstrated statistically significant superiority over placebo on the primary endpoint of bipolar recurrence.
U 12-mjesečnom ispitivanju prevencije relapsa u bolesnika s epizodom manije koji su postigli remisiju na olanzapinu, a zatim su randomizirani u skupinu koja je uzimala olanzapin ili placebo, olanzapin je pokazao statistički značajnu prednost nad placebom u primarnoj mjeri ishoda ‒ relapsu bipolarnog poremećaja.
In a 12-month recurrence prevention study in manic episode patients who achieved remission on olanzapine and were then randomised to olanzapine or placebo, olanzapine demonstrated statistically significant superiority over placebo on the primary endpoint of bipolar recurrence.
U 12-mjesečnom ispitivanju prevencije relapsa u bolesnika s epizodom manije koji su postigli remisiju na olanzapinu, a zatim su randomizirani u skupinu koja je uzimala olanzapin ili placebo, olanzapin je pokazao statistički značajnu prednost nad placebom u primarnoj mjeri ishoda – relapsu bipolarnog poremećaja.